Our History

History of IDH

With over 40 years of industry experience and strategic expansion, IDH has built a strong market position across products and geographies, with a scalable platform that is set for further strong growth.

Establishment of MK Lab

Dr. Moamena Kamel, Professor of Immunology at Cairo University, founds the MK Lab which later merges with Al Mokhtabar in 2004

1979

Al Borg was founded

Founded by a group of four doctors, Al Borg is the first medical laboratory in Egypt to have an efficient hub, spoke and spike model

1990

IDH established by Abraaj

Abraaj acquires 76.8% of Al Borg to establish IDH Caymans

Branches(a) : 127

2008

Expansion of IDH

Acquisition of 99.9% stake in Molecular Diagnostics Centre

Branches(a) : 154

2009

Expansion of product offering

Acquisition of 54.98% stake in Medical Genetics Centre

Increase of stake in Al Borg to 80% post its delisting

Branches(a) : 195

2010

Building infrastructure and scale

Penetration in Sudan and Jordan comes with acquisition of Ultralab and Biolab, respectively

Branches(a) : 210

2011

Creating a leading platform

Acquisition of 99.9% of Al Mokhtabar (Al Borg’s biggest competitor)

Increase of stake in Al Borg to 99.3%

Branches(a) : 214

2012

Integration and further expansion

Establishes the largest automated lab in Egypt

Diversifies into adjacent medical services

Branches(b) : 262 (2013); 288 (2014)

2013

Successful completion of IPO on the LSE

Standard listing on the London Stock Exchange (LSE)

50% offering at USD 4.45 per share

Market capitalization of USD 667.5 mn

2015

Completes investment in Nigeria

Establishes Dynasty Group Holdings, a JV between IDH and Man Capital, to invest in Eagle Eye Echo-Scan Services Limited, a leading medical diagnostics business based in Nigeria.

LAUNCHES AL BORG SCAN

Expands into the high-value, adjacent radiology segment through the launch of Al Borg Scan.

Branches (b): 414

2018

Launches new subsidiary “Wayak” to offer data-driven healthcare support

Wayak will leverage the Group’s patient database to capture new growth opportunities in the healthcare management space and offer targeted services to its customers.

Branches (b): 452

2019

Adapts to continue growing

Despite the unprecedented difficulties related to Covid-19, IDH’s swift service adjustments to changing market
dynamics allowed for yet another year of solid top- and bottom-line growth.

Branches (b): 481

2020

A record-breaking year

IDH completed its dual-listing on EGX; delivered record-breaking top- and bottom-line results; transformed service offering and delivery capabilities setting the foundations for long-term growth.

Branches (b): 502

2021

A new chapter

Despite significant macroeconomic difficulties in its home market, IDH maintained the growth of its conventional business while signing an agreement to expand its footprint to a fifth market, Saudi Arabia.

Branches (b): 552

2022

Fostering Sustainable Growth

Despite continued economic pressures in three of IDH’s markets, the Company posted impressive top-line growth, even including Covid contributions in 2022.

Branches (b): 601

2023

Broadening our reach

IDH officially launches Saudi Arabian operations adding a new market to its portfolio. In August, the Company successfully concludes its delisting process from the Egyptian Exchange (EGX) maintaining its standard listing on the London Stock Exchange (LSE).

2024

Note:

(a) Branches refer to core operations of Al Borg and Al Mokhtabar in Egypt
(b) Branches refer to the IDH group

Source: Company data